Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5609143 | 0.84 | APP (0.55) | APPMAPK1THRBALDH1A1KDM4E | |
| SCHEMBL18088138 | 0.84 | APP (0.55) | APPSYKMAPK1CYP1A2CYP2C19 | |
| SCHEMBL8349740 | 0.83 | SYK (0.50) | SYKMAPK1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL15723552 | 0.82 | MAPK1 (0.58) | SYKMAPK1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL1545732 | 0.82 | APP (0.54) | APPMAPK1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL19743630 | 0.82 | APP (0.54) | APPSYKMAPK1THRBKDM4E | |
| SCHEMBL8310702 | 0.82 | APP (0.54) | APPSYKMAPK1THRBALDH1A1 | |
| SCHEMBL13169873 | 0.82 | THRB (0.60) | APPCYP1A2CYP2C19THRBKMT2A | |
| SCHEMBL21600883 | 0.81 | SYK (0.49) | SYKMAPK1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL24861162 | 0.80 | HTR1B (0.50) | APPMAPK1ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117916237-A | Amino aryl integrin agonist compounds | 德克萨斯心脏研究所 | 2024-04-19 | — | — | CN | disclosed |
| CN-115209897-A | Rapamycin analogs and uses thereof | 安纳库利亚治疗公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-113302175-A | Bicyclic compounds | 维瓦斯治疗公司 | 2021-08-24 | — | — | CN | disclosed |
| EP-3003314-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | KALA PHARMACEUTICALS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-1944305-B1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-7572915-B2 | 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7572915-B2 | 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| EP-1944305-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | PDE3B, PDE4B, PDE4A | APP 3282/4885SYK 1326/4885MAPK1 2233/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | APP 3282/4885SYK 1326/4885MAPK1 2233/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | APP 3282/4885SYK 1326/4885MAPK1 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.